Kincell Bio promotes Bruce Thompson to President and Chief Technology Officer. The cell therapy-focused CDMO has also elevated Melodie Bryce to Chief Quality Officer and Matt Haines to Chief Operations Officer. Cell therapy-focused contract development and manufacturing organisation (CDMO) Kincell Bio has made a trio of promotions to its senior leadership team. * Mandatory essentials of USP General Chapter 41 -calibration, minimum weight, repeatability and accuracy requirements, and performance checks * Informational statements of USP General Chapter 1251 - the concept of a safety factor * Performance checks - general requirements Its speaker will address specific USP-related questions in a Q&A format at the end of the webinar. The US firm has promoted its founding CEO Bruce Thompson to President and Chief Technology Officer and elevated Melodie Bryce to Chief Quality Officer and Matt Haines to Chief Operations Officer. Kincell Bio's Chief Executive Officer Larry Pitcher said: "Bruce, Melodie and Matt have demonstrated exceptional leadership and expertise, and their expanded roles further strengthen its ability to deliver innovative, high-quality solutions for its clients while accelerating access to transformative therapies for patients. "Together with our highly skilled teams, we will continue to expand our clinical development and commercial supply infrastructure, accelerate technology transfer and strengthen our commitment to delivering life-changing cell therapies efficiently and reliably." Thompson's prior leadership roles include VP of Process Sciences at Lyell Immunopharma. He has also held technical and operational leadership positions at Resilience and Fred Hutchinson Cancer Research Center, where he led GMP manufacturing of cell and gene therapy products. Bryce has nearly three decades of experience in quality leadership, spanning cell therapy, antibody and aseptic production, previously held senior quality leadership roles at KBI Biopharma, Cognate BioServices, Matica Biotechnology and Fujifilm Diosynth Biotechnologies. Meanwhile, Haines brings to his new role over 20 years of biotech experience, specialising in manufacturing sciences and operations at Biogen, Amgen and Merck. Before joining Kincell, he served as VP of Manufacturing Operations at Inceptor Bio, a cell therapy innovator, and Senior Director at AveXis/Novartis Gene Therapies.

Kincell Bio promotes Lawrence Pitcher to CEO. Pitcher offers experience scaling cell and gene therapy manufacturing operations and aligning them with client and patient needs. Kincell Bio, a contract development and manufacturing organization (CDMO) in cell therapy, has promoted Lawrence "Larry" Pitcher to Chief Executive Officer, effective immediately. Pitcher succeeds Mark R. Bamforth OBE, who guided the company through a successful phase of growth as CEO and will continue to support the transition in a strategic capacity as Executive Chair of the Board. "Larry has a proven track record scaling cell and gene therapy manufacturing operations and aligning them with client and patient needs," said Mark R. Bamforth OBE. "His leadership of our operational capabilities positions Kincell Bio to better serve our clients as they progress into late-stage trials and commercial launch." As COO since March 2025, Pitcher has been instrumental in applying his experience to expanding Kincell Bio's production capabilities, processes, and systems to support pivotal and commercial-stage cell therapies. Prior to joining Kincell Bio, he served as VP & GM at Catalent's Maryland gene therapy site where he cultivated robust commercial manufacturing operations and drove significant revenue and profitability gains. His earlier roles include leadership positions at Thermo Fisher, Brammer Bio, and RTI Surgical across Europe and the U.S., where he delivered consistent operational excellence and growth. With a B.S. in Industrial Engineering from Western Michigan University and an MBA from the University of Florida, Pitcher brings technical expertise and strategic vision to the CEO role. He takes the helm at a pivotal time as Kincell Bio accelerates cell therapy product supply from its Research Triangle Park, NC, and Gainesville, FL sites. "I'm honored to assume the CEO role at Kincell Bio. Together with our skillful teams, we will expand our clinical development and commercial supply infrastructure, accelerate technology transfer, and strengthen our commitment to deliver life-changing cell therapies efficiently and reliably," Pitcher shared.

Kincell Bio announced the completion of a $22 million round, led by a new investor, NewSpring Capital through its dedicated healthcare strategy, NewSpring He...